In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid — an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Half of patients who experienced virologic rebound after ...

Price worries, bureaucratic obstacles, and “I’m-over-COVID-itis” are slowing uptake of Paxlovid, a drug that’s complicated to take but often effective. Since late December, when Pfizer shifted to ...

Taking Paxlovid for 15 days is safe, but it doesn’t reduce symptoms of long COVID, according to a Stanford (Calif.) Medicine study published June 7 in JAMA Internal Medicine. Long COVID affects about ...

SAN FRANCISCO -- The popular COVID treatment, Paxlovid, does not significantly lower the risk of "long COVID" for people who are vaccinated. In a new study from UCSF, researchers found that patients ...

Paxlovid helps prevent severe COVID-19, but it also might significantly increase a person's risk of a rebound case, a new study confirms. About 1 in 5 people taking Paxlovid recovered and tested ...

Paxlovid is an antiviral therapy that helps your body fight off COVID-19 faster and more effectively. In one clinical trial, Paxlovid was 89% effective in reducing hospitalization and death in ...

Never miss a story with The Brief, our free newsletter. Keep tabs on Texas politics and policy with our morning newsletter. The Texas Tribune Independent news. Trusted by Texans. About The Texas ...

Add Yahoo as a preferred source to see more of our stories on Google. Paxlovid, an anti-viral approved for emergency use in the treatment of COVID, has been increased by the federal government. (Photo ...